Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.09
NAS:BDSI's Cash-to-Debt is ranked lower than
80% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:BDSI: 1.09 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BDSI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12  Med: 6.02 Max: No Debt
Current: 1.09
Equity-to-Asset -0.34
NAS:BDSI's Equity-to-Asset is ranked lower than
96% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:BDSI: -0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BDSI' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.52  Med: 0.29 Max: 0.81
Current: -0.34
-2.52
0.81
Piotroski F-Score: 1
Altman Z-Score: -10.61
Beneish M-Score: -0.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -411.26
NAS:BDSI's Operating Margin % is ranked lower than
67% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:BDSI: -411.26 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BDSI' s Operating Margin % Range Over the Past 10 Years
Min: -10722.77  Med: -445.27 Max: 63.88
Current: -411.26
-10722.77
63.88
Net Margin % -431.87
NAS:BDSI's Net Margin % is ranked lower than
69% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:BDSI: -431.87 )
Ranked among companies with meaningful Net Margin % only.
NAS:BDSI' s Net Margin % Range Over the Past 10 Years
Min: -12468.81  Med: -260.99 Max: 6552.47
Current: -431.87
-12468.81
6552.47
ROE % -948.65
NAS:BDSI's ROE % is ranked lower than
98% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:BDSI: -948.65 )
Ranked among companies with meaningful ROE % only.
NAS:BDSI' s ROE % Range Over the Past 10 Years
Min: -957  Med: -202.37 Max: 6.13
Current: -948.65
-957
6.13
ROA % -86.33
NAS:BDSI's ROA % is ranked lower than
83% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:BDSI: -86.33 )
Ranked among companies with meaningful ROA % only.
NAS:BDSI' s ROA % Range Over the Past 10 Years
Min: -133.16  Med: -60.42 Max: 124.67
Current: -86.33
-133.16
124.67
ROC (Joel Greenblatt) % -1489.91
NAS:BDSI's ROC (Joel Greenblatt) % is ranked lower than
67% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:BDSI: -1489.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BDSI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10265.14  Med: -991.94 Max: 2073.85
Current: -1489.91
-10265.14
2073.85
3-Year Revenue Growth Rate -1.00
NAS:BDSI's 3-Year Revenue Growth Rate is ranked lower than
59% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:BDSI: -1.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:BDSI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -64.8  Med: 12.85 Max: 418.2
Current: -1
-64.8
418.2
3-Year EBITDA Growth Rate -7.10
NAS:BDSI's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:BDSI: -7.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:BDSI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.3  Med: -1.85 Max: 53.4
Current: -7.1
-47.3
53.4
3-Year EPS without NRI Growth Rate -6.10
NAS:BDSI's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:BDSI: -6.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:BDSI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.1  Med: 16.8 Max: 68.4
Current: -6.1
-68.1
68.4
GuruFocus has detected 4 Warning Signs with BioDelivery Sciences International Inc $NAS:BDSI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BDSI's 10-Y Financials

Financials (Next Earnings Date: 2017-06-17 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BDSI Guru Trades in Q1 2016

Jim Simons 633,100 sh (+170.44%)
Chuck Royce 1,837,800 sh (+23.52%)
» More
Q2 2016

BDSI Guru Trades in Q2 2016

Jim Simons 1,713,600 sh (+170.67%)
Chuck Royce 1,382,900 sh (-24.75%)
» More
Q3 2016

BDSI Guru Trades in Q3 2016

Chuck Royce 1,542,900 sh (+11.57%)
Jim Simons 929,275 sh (-45.77%)
» More
Q4 2016

BDSI Guru Trades in Q4 2016

Jim Simons Sold Out
Chuck Royce 551,200 sh (-64.28%)
» More
» Details

Insider Trades

Latest Guru Trades with BDSI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RGLS, NAS:LPTX, OTCPK:PMCB, NAS:SNSS, NAS:CASI, OTCPK:HPPI, AMEX:ATNM, OTCPK:ARTH, NAS:SBPH, OTCPK:HBPCF, NAS:VCEL, NAS:AXSM, NAS:CXRX, NAS:LIFE, OTCPK:CYDY, AMEX:NAVB, NAS:ORMP, NAS:SRRA, NAS:EIGR, NAS:NEPT » details
Traded in other countries:BD5.Germany,
Headquarter Location:USA
BioDelivery Sciences International Inc along, with its subsidiaries, is a specialty pharmaceutical company that is developing and commercializing new applications of approved therapeutics to address important unmet medical needs.

BioDelivery Sciences International is a biotechnology company that specializes in pain management and addiction medicine. The company's products and candidates are based on BioErodible MucoAdhesive, a proprietary B drug delivery technology. BEMA is a small, erodible polymer film for application to the buccal mucosa, which is used in approved products and candidates such as ONSOLIS (fentanyl buccal soluble film) for treating cancer pain; BUNAVAIL (buprenorphine and naloxone buccal film) to treat opioid dependence; and product candidate BELBUCA (formerly referred to as BEMA Buprenorphine), which aims to treat chronic pain.

Ratios

vs
industry
vs
history
PS Ratio 5.85
BDSI's PS Ratio is ranked higher than
63% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. BDSI: 5.85 )
Ranked among companies with meaningful PS Ratio only.
BDSI' s PS Ratio Range Over the Past 10 Years
Min: 0.73  Med: 16.38 Max: 1156.67
Current: 5.85
0.73
1156.67
EV-to-EBIT -1.69
BDSI's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. BDSI: -1.69 )
Ranked among companies with meaningful EV-to-EBIT only.
BDSI' s EV-to-EBIT Range Over the Past 10 Years
Min: -58.8  Med: -3.1 Max: 32.5
Current: -1.69
-58.8
32.5
EV-to-EBITDA -1.72
BDSI's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. BDSI: -1.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
BDSI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -118.3  Med: -3.3 Max: 23
Current: -1.72
-118.3
23
Current Ratio 2.17
BDSI's Current Ratio is ranked lower than
72% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. BDSI: 2.17 )
Ranked among companies with meaningful Current Ratio only.
BDSI' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 1.09 Max: 5.84
Current: 2.17
0.03
5.84
Quick Ratio 2.00
BDSI's Quick Ratio is ranked lower than
71% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. BDSI: 2.00 )
Ranked among companies with meaningful Quick Ratio only.
BDSI' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 1.09 Max: 5.84
Current: 2
0.03
5.84
Days Inventory 124.44
BDSI's Days Inventory is ranked higher than
51% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. BDSI: 124.44 )
Ranked among companies with meaningful Days Inventory only.
BDSI' s Days Inventory Range Over the Past 10 Years
Min: 67.55  Med: 96.06 Max: 124.44
Current: 124.44
67.55
124.44
Days Sales Outstanding 83.80
BDSI's Days Sales Outstanding is ranked lower than
64% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. BDSI: 83.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
BDSI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.49  Med: 48.65 Max: 650.89
Current: 83.8
3.49
650.89
Days Payable 304.66
BDSI's Days Payable is ranked higher than
88% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. BDSI: 304.66 )
Ranked among companies with meaningful Days Payable only.
BDSI' s Days Payable Range Over the Past 10 Years
Min: 304.66  Med: 564.49 Max: 1275.75
Current: 304.66
304.66
1275.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.30
BDSI's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. BDSI: -12.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BDSI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -38.1  Med: -18 Max: -8
Current: -12.3
-38.1
-8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.36
BDSI's Price-to-Median-PS-Value is ranked higher than
85% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BDSI: 0.36 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BDSI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.85 Max: 14.65
Current: 0.36
0.08
14.65
Earnings Yield (Greenblatt) % -59.10
BDSI's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. BDSI: -59.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BDSI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -61.7  Med: 66.3 Max: 148
Current: -59.1
-61.7
148

More Statistics

Revenue (TTM) (Mil) $15.55
EPS (TTM) $ -1.26
Beta1.46
Short Percentage of Float8.06%
52-Week Range $1.50 - 3.78
Shares Outstanding (Mil)54.80

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 49 43
EPS ($) -0.59 -0.55
EPS without NRI ($) -0.59 -0.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BDSI

Headlines

Articles On GuruFocus.com
BioDelivery Sciences to Present at the Deutsche Bank 42nd Annual Health Care Conference Apr 26 2017 
BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in FDA's Orange Book Fur Mar 31 2017 
Weekly CFO Buys Highlight: BioDelivery Sciences International, TheStreet, Antares Pharma Mar 27 2016 
Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and H Feb 02 2014 
Weekly CFO Sells Highlight: BDSI, LNKD, VRSK, ABMD, AGX Jul 17 2012 
BioDelivery Sciences International Inc. Reports Operating Results (10-K/A) Nov 19 2010 
BioDelivery Sciences International Inc. Reports Operating Results (10-Q) Aug 09 2010 
BioDelivery Sciences International Inc. Reports Operating Results (10-Q) Aug 09 2010 
BioDelivery Sciences International Inc. (BDSI) CEO Mark A Sirgo buys 4,022 Shares Jun 10 2010 
BioDelivery Sciences International Inc. (BDSI) CEO Mark A Sirgo buys 4,450 Shares May 24 2010 

More From Other Websites
BioDelivery Sciences to Present at the Deutsche Bank 42nd Annual Health Care Conference Apr 26 2017
BioDelivery (BDSI) Down 15% Since Earnings Report: Can It Rebound? Apr 18 2017
New cash, patents boost optimism at Raleigh's BioDelivery Sciences Apr 04 2017
BioDelivery to Grant New Patents for its Marketed Drugs Apr 03 2017
Blog Coverage BioDelivery Extends its Patent Portfolio; Acquires Extended Patents for BELBUCA,... Apr 03 2017
BioDelivery Sciences Secures Two Patents Mar 31 2017
BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in FDA's Orange Book... Mar 31 2017
BioDelivery Sciences International and Rexahn Pharmaceuticals See Share Values Rise Slightly Mar 28 2017
BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet Mar 20 2017
Edited Transcript of BDSI earnings conference call or presentation 17-Mar-17 12:00pm GMT Mar 17 2017
BioDelivery Q4 Loss Wider Than Expected; Revenues in Line Mar 17 2017
BioDelivery reports 4Q loss Mar 17 2017
BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016... Mar 17 2017
BioDelivery Sciences Announces Three Data Presentations on BELBUCA® at the American Academy of Pain... Mar 16 2017
BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2016... Mar 09 2017
BioDelivery Sciences to Present at the 29th Annual ROTH Conference Mar 08 2017
Has Biodelivery Sciences Finally Turned the Corner? Mar 06 2017
BioDelivery (BDSI): What's in Store this Earnings Season? Mar 06 2017
Endo profit, sales beat as the drugmaker enters transition phase Feb 28 2017
BioDelivery Sciences Secures Debt Financing with CRG Feb 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)